Comparison of estrogens and estrogen metabolites in human breast tissue and urine

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Taioli, Emanuela ^a,b   Im, Annie ^c   Xu, Xia ^d   Veenstra, Timothy D ^d   Ahrendt, Gretchen ^c   Garte, Seymour ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 OXOESTRADIOL; 16ALPHA HYDROXYESTRONE; 17 EPIESTRIOL; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 HYDROXYESTRONE 3 METHYL ETHER; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; CYTOCHROME P450 1B1; EPIESTRIOL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN METABOLITE; ESTRONE; UNCLASSIFIED DRUG; CYP1B1 PROTEIN, HUMAN; CYTOCHROME P450; LEUCINE; VALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BREAST LEVEL; ESTROGEN METABOLISM; FEMALE; HORMONE DETERMINATION; HORMONE URINE LEVEL; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; BREAST; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENE FREQUENCY; GENETICS; METABOLISM; METABOLOME; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; URINE;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ESTRADIOL; ESTROGENS; FEMALE; GENE FREQUENCY; HUMANS; LEUCINE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VALINE;

EID: 77955058956     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-93     Document Type: Article

References (36)

1. Bernstein L. Epidemiology of Endocrine-Related Risk Factors for Breast Cancer. J Mammary Gland Biol Neopl 2002, 7(1):3-15.
2. Henderson BE, Fiegelson HS. Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433. 10.1093/carcin/21.3.427, 10688862.
3. Key TJ, Appleby PN, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. JNCI 2002, 94:606-616.
4. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990, 50:7415-7421.
5. Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996, 17:2279-2284. 10.1093/carcin/17.11.2279, 8968038.
6. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776, 16421368.
7. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res 1998, 58:2269-2277.
8. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003, 72:877-883. 10.1016/S0024-3205(02)02305-6, 12493568.
9. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006, 54:72-77. 10.1016/j.maturitas.2005.08.010, 16213115.
10. Sepkovic DW, Bradlow HL. Estrogen hydroxylation--the good and the bad. Ann N Y Acad Sci 2009, 1155:57-67. 10.1111/j.1749-6632.2008.03675.x, 19250192.
11. Paracchini V, Pedotti P, Raimondi S, Garte S, Bradlow HL, Sepkovic DW, Taioli E. A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med 2005, 43(7):702-706. 10.1515/CCLM.2005.119, 16207128.
12. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci 1982, 79:3047-3051. 10.1073/pnas.79.9.3047, 346346, 6953448.
13. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16α-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984, 20:1077-1081. 10.1016/0022-4731(84)90021-9, 6727352.
14. Cauley J, Zmuda J, Danielson ME, Ljung BM, Bauer DC, Cummings SR, Kuller LH. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003, 14:740-744. 10.1097/01.ede.0000091607.77374.74, 14569192.
15. Fowke J, Qi D, Bradlow HL, Shu XO, Gao YT, Cheng JR, Jin F, Zheng W. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre-versus post-treatment collection. Steroids 2003, 68:65-72. 10.1016/S0039-128X(02)00116-2, 12475724.
16. Kabat G, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997, 6(7):505-509.
17. Kabat G, O'Leary ES, Gammon MD, Sepkovic DW, Teitelbaum SL, Britton JA, Terry MB, Neugut AI, Bradlow HL. Estrogen metabolism and breast cancer. Epidemiology 2006, 17:80-88. 10.1097/01.ede.0000190543.40801.75, 16357599.
18. Meilahn E, DeStavola B, Allen D, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998, 78(9):1250-1255. 2063014, 9820189.
19. Modugno F, Kip K, Cochrane B, Kuller L, Klug TL, Rohan TE, Chlebowski RT, Lasser N, Stefanick ML. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006, 118(5):1292-1301. 10.1002/ijc.21487, 16161054.
20. Muti P, Bradlow H, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F. Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11:635-640. 10.1097/00001648-200011000-00004, 11055622.
21. Ursin G, London S, Stanczyk F, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. JNCI 1999, 91:1067-1072.
22. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005, 14(9):2137-2141. 10.1158/1055-9965.EPI-04-0934, 16172222.
23. Ursin G, London S, Yang D, Tseng CC, Pike MC, Bernstein L, Stanczyk FZ, Gentzschein E. Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 2002, 72:139-143. 10.1023/A:1014896417653, 12038704.
24. van Landeghem AAJ, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985, 45:2900-2906.
25. Thijssen JHH, Blankenstein MA, Miller WR, Milewicz A. Estrogens in tissues: uptake from the peripheral circulation or local production. Steroids 1987, 50:297-306. 10.1016/0039-128X(83)90079-X, 3504065.
26. Vermeulen A, Deslypere JP. Biosynthesis of active oestrogens in the breast. Oestrogen and the Human Breast 1989, 195-201. Edinburgh: Royal Society of Edinburgh, Beck JS.
27. Castagnetta L, Granata O, Blasi L, Cassetti A, Comito L, Cavasino V, Polito L, Carruba G. Recent studies on metabolism and concentrations of estrogens in breast cancer tissues and cells. Breast Cancer Detect Prev 1992, 16:S65-S70.
28. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, Saavedra JE, Keefer LK, Ziegler RG. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005, 77(20):6646-6654. 10.1021/ac050697c, 16223252.
29. Blonder J, Johann DJ, Veenstra TD, Xiao Z, Emmert-Buck MR, Ziegler RG, Rodriguez-Canales J, Hanson JA, Xu X. Quantitation of steroid hormones in thin fresh frozen tissue sections. Anal Chem 2008, 80(22):8845-8852. 10.1021/ac801402a, 18937426.
30. Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas 2002, 43(1):1-10. 10.1016/S0378-5122(02)00141-X, 12270576.
31. Castagnetta LA, Granata OM, Traina A, Ravazzolo B, Amoroso M, Miele M, Bellavia V, Agostara B, Carruba G. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 2002, 8:3146-3155.
32. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM, Cavalieri EL. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003, 24:697-702. 10.1093/carcin/bgg004, 12727798.
33. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG. A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 2008, 17:3411-8. 10.1158/1055-9965.EPI-08-0355, 19064556.
34. Im A, Vogel VG, Ahrendt G, Lloyd S, Ragin C, Garte S, Taioli E. Urinary estrogen metabolites in women at high risk for breast cancer. Carcinogenesis 2009, 30(9):1532-5. 10.1093/carcin/bgp139, 19502596.
35. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008, 122(9):1949-57. 10.1002/ijc.23329, 18098283.
36. Hakkola J, Pasanen M, Pelkonen O, Hukkanen J, Evisalmi S, Anttila S, Rane A, Mäntylä M, Purkunen R, Saarikoski S, Tooming M, Raunio H. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placental and cultured cells. Carcinogenesis 1997, 18:391-397. 10.1093/carcin/18.2.391, 9054634.